-

NovaBay Pharmaceuticals Announces the Availability of KN95 Disposable Masks on Avenova.com

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces the availability of KN95 disposable air filter masks on the Company’s website Avenova.com. The masks are being sold at a price of $59.99 for a package containing 10 masks or $149.99 for a package containing 30 masks. KN95-rated masks are effective at filtering out at least 95% of airborne particles, including microorganisms, dust, pollen and air pollution.

“In light of the shortage of protective masks, we have tapped into our global health supplier network to procure and make available a high-quality, KN95-rated product at the most reasonable price possible,” said Justin Hall, NovaBay CEO. “We received our first shipment of KN95 masks last week, which sold out online very quickly, and expect a second large inventory of masks to be available for shipment today. To meet the immediate need, we had the masks flown in on a rush basis. We have direct access to a large supplier of KN95 masks and encourage organizations ordering quantities of 50,000 or more to contact us directly at 1-800-890-0329 for special pricing.

“We plan to continue providing KN95 masks on Avenova.com for as long as the demand remains,” Mr. Hall added. “In these most unusual of circumstances, it’s gratifying for the NovaBay team to carry out our commitment to marshal all of our talents and resources to benefit the health and wellbeing of people everywhere. We will continue to be here to help accomplish this objective during and after this crisis is over.”

The NK95 disposable masks are constructed with a three-layer filtration system of nonwoven soft and breathable fiber for effective protection. The masks feature extra soft and comfortable elastic ear loops that will not apply pressure to the ears during use and have an adjustable nose bridge strip. The masks come in a single size that fits most faces. They are non-toxic, odorless, non-irritating, contain no dyes and are hypoallergenic and gentle on the skin. The disposable masks should be replaced daily for best hygiene and are ideal for one-time use in a non-medical setting.

The KN95 air filter masks are manufactured by Earntz Nonwoven Co., Ltd. and are CE certified for FFP2 protective mask (EN 149-2001) and meet KN95-level requirements (GB 2626-2006).

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, CELLERX® for the aesthetic dermatology market NEUTROPHASE® for wound care market.

Forward-Looking Statements

This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our current re-branding strategy, the launch of a new marketing initiative, and the impact any of these efforts may have on our future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to consumer acceptance of our new branding, and any potential damage to our established goodwill in the marketplace. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Socialize and Stay informed on NovaBay’s Progress
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Visit NovaBay’s Website

Contacts

NovaBay Contact
Justin Hall
CEO and General Counsel
510-899-8800
jhall@novabay.com

Investor Contact
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

NovaBay® Pharmaceuticals, Inc.

NYSEAM:NBY

Release Versions

Contacts

NovaBay Contact
Justin Hall
CEO and General Counsel
510-899-8800
jhall@novabay.com

Investor Contact
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

More News From NovaBay® Pharmaceuticals, Inc.

NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft

EMERYVILLE, Calif. & POMPANO BEACH, Fla.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces the commercial launch of Avenova Allograft to eyecare professionals across the U.S. through its physician-dispensed channel. This prescription product is the only optic allograft manufactured using BioStem Technologies, Inc.’s (OTC: BSEM) proprietary process and is intended for use as a protective covering during the repair of ocular surfaces. The product launch follows a prev...

NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft

EMERYVILLE, Calif. & POMPANO BEACH, Fla.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and BioStem Technologies, Inc. (OTC: BSEM) announce an agreement under which NovaBay has been granted the right to commercialize BioStem Technologies’ Amniotic Tissue Allograft, which is intended for use as a protective covering during the repair of ocular surfaces. Amniotic Tissue Allograft provides a protective environment or covering for repair of the cornea and conjunctiva, helping...

NovaBay Pharmaceuticals Reports Second Quarter 2023 Financial Results

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and six months ended June 30, 2023 and provides a business update. “Net product revenue reached $4.6 million for the quarter, up 26% from the prior year as we benefited from a particularly strong quarter in our wound care segment,” said Justin Hall, NovaBay CEO. “We continue to control expenses by optimizing digital marketing programs, which led to a 16% year-over-yea...
Back to Newsroom